Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have revolutionized the treatment of advanced EGFR‐mutated non‐small cell lung cancer (NSCLC) with prolonged overall survival (OS) compared with platinum‐based doublet chemotherapy in several phase III trials [1, 2, 3, 4, 5]. Here, EGFR is linked to non-small cell lung carcinoma.